Estrella Immunopharma Inc

Research Estrella Immunopharma Inc (ESLA) on Bullrun: market cap USD 44.33M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerESLA
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 44.33M
• Financial periodFY2025
• Net income-USD 13.06M

Valuation Snapshot

latest market cap is USD 44.33M.

About Estrella Immunopharma Inc

Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus.

Frequently asked questions

What is Estrella Immunopharma Inc's market cap?

Estrella Immunopharma Inc's market capitalization is USD 44.33M.

What does Estrella Immunopharma Inc do?

Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma;